跳至主要内容
临床试验/ACTRN12619001426178
ACTRN12619001426178招募中未知

The Thoracic Society of Australia and New Zealand -Australasian Severe Asthma Benralizumab Registry

The Thoracic Society of Australia and New Zealand0 个研究点目标入组 200 人开始时间: 2019年10月15日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.adults aged 18 years and over;
  • 2.provision of informed consent prior to any study specific procedures;
  • 3.confirmed asthma diagnosis;
  • 4.using maximum therapy [inhaled high dose of corticosteroid and 2nd controller];
  • 5.uncontrolled asthma [currently, or on reduction in maximal therapy], which constitutes each of:
  • a.poor symptom control: ACQ-5>=2;
  • b.>=1 severe exacerbation in the past 12 months;
  • c.airflow obstruction: FEV1<80% predicted;
  • 6.optimised asthma management skills;
  • 7.triggers and relevant co-morbidity have been assessed and managed;
  • 8.eosinophilic asthma as determined from airway sample (induced sputum, BAL >3%) or peripheral blood sample;
  • 9.Blood eosinophil count >=300/µL in the previous 12 months;

排除标准

  • 1.unable to complete study data collection requirements, unable to participate over 2 year period;
  • 2.people highly dependent on medical care;
  • 3.cognitive impairment preventing completion of data collection forms.

研究者

发起方
The Thoracic Society of Australia and New Zealand

相似试验